Vusolimogene oderparepvec-wtpg and nivolumab earned accelerated approval to treat patients with advanced melanoma after PD-1 therapy. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev) in combination with...
Lutetium Lu 177 vipivotide tetraxetan is the first radioligand therapy approved for metastatic prostate cancer that responds to hormone treatment. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan...
FDA approves pembrolizumab and enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex)...
The allogeneic regulatory T cell therapy was designed to improve HSCT outcomes in patients with hematological malignancies. The U.S. Food and Drug Administration (FDA) has approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem...
Sacituzumab govitecan-hziy was approved as a monotherapy or in combination with pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for two indications in adult patients with unresectable locally advanced...
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration (FDA) has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), with or without pertuzumab (Perjeta),...
Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial sarcoma. The U.S. Food and Drug Administration (FDA) has granted full approval to afamitresgene autoleucel...
The FDA approved capivasertib with abiraterone and prednisone for adults whose metastatic prostate cancer may be sensitive to hormone therapy. The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) with abiraterone and...
Under new approval, the drug can be given with immunotherapy to help reduce risk of recurrence after surgery in patients with clear cell renal cell carcinoma. The U.S. Food and Drug Administration (FDA) has...
The FDA approved durvalumab with Bacillus-Calmette Guérin for patients with high-risk, BCG-naïve non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with Bacillus Calmette-Guérin (BCG) for...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More